Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Cobimetinib Plus Atezolizumab Active in Microsatellite Stable mCRC

June 29th 2016

Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.

Dr. Raghav on HER2 Amplification in Patients With CRC

June 24th 2016

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer.

Expert Sheds Light on Promising Immunotherapy Combo Data in mCRC

June 23rd 2016

Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.

USPSTF Updates CRC Screening Guideline

June 21st 2016

The United States Preventative Services Task Force recommends screening for colorectal cancer using traditional colonoscopy or one of 7 tests at various frequencies for all patients aged 50 to 75.

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

June 15th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.

Atezolizumab and Cobimetinib Regimen Shows Activity in CRC

June 15th 2016

In patients with advanced colorectal cancer, the combination regimen of cobimetinib (Cotellic) and atezolizumab (Tecentriq) was found to demonstrate clinical activity as well as have a good safety profile.

Process Unclear on How to Identify Mutations in Non-Lynch Syndrome Patients With CRC

June 9th 2016

Results of an analysis presented at the 2016 ASCO Annual Meeting demonstrate the difficulty in determining the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer (CRC) who do not harbor Lynch syndrome.

Nivolumab/Ipilimumab Combo Active in Microsatellite Instability-High mCRC

June 6th 2016

Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.

Expert Shares Significance of Approved Agents in CRC

June 2nd 2016

Tanios Bekaii-Saab, MD, discusses the use of both regorafenib and TAS-102, as well as the potential role immunotherapy could have within colorectal cancer.

Polyp Mutations May Hold Key to CRC Prevention

May 31st 2016

Precancerous colon polyps exhibit many of the same driver mutations that fuel the development of colorectal cancer.

Tumor Location Linked to Survival Outcomes in Metastatic Colorectal Cancer

May 19th 2016

Survival outcomes in patients with metastatic colorectal cancer were significantly longer among those with tumors originating on the left versus the right side of the colon, according to a retrospective analysis of the phase III 80405 trial.

SIRFLOX Study Design Confounds Primary Efficacy Findings

April 27th 2016

Navesh K. Sharma, DO, PhD, discusses findings on a study looking at the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in liver metastatic colorectal cancer.

Numerous Frontline CRC Options Allow Individualized Approach

April 23rd 2016

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.

Dr. Bekaii-Saab on Active Agents for the Treatment of Colorectal Cancer

April 23rd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

Genomics Studies Opening Up Fresh Options for CRC Research

April 22nd 2016

Raju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.

Dr. Berger on Noninvasive Screening Tool for CRC

April 19th 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).

Dr. Udit Verma on Regorafenib in Patients With mCRC

April 13th 2016

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.

Biomarker Leads to New Potential CRC Treatment

April 13th 2016

Deficiency in the protein NOD-like receptor X1 (NLRX1) could represent a potential biomarker to predict response to therapies in patients with colorectal cancer.

Expert Discusses Microsatellite Instability, Immunotherapy in CRC

April 11th 2016

Zsofia K. Stadler, MD, provides extensive insight on microsatellite instability in colorectal cancer, the biology of and screening for MSI tumors, and the potential impact immunotherapy could have on the treatment paradigm.

Ensituximab Shows Promise in Refractory mCRC

April 8th 2016

Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer without contributing significant toxicity.